1. Home
  2. LASR vs ACAD Comparison

LASR vs ACAD Comparison

Compare LASR & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo nLIGHT Inc.

LASR

nLIGHT Inc.

N/A

Current Price

$32.74

Market Cap

4.1B

Sector

Technology

ML Signal

N/A

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$17.18

Market Cap

4.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LASR
ACAD
Founded
2000
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.4B
IPO Year
2018
2000

Fundamental Metrics

Financial Performance
Metric
LASR
ACAD
Price
$32.74
$17.18
Analyst Decision
Strong Buy
Buy
Analyst Count
9
20
Target Price
★ $59.50
$30.21
AVG Volume (30 Days)
941.2K
★ 2.4M
Earning Date
11-05-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
62.99
★ 69.12
EPS
N/A
★ 0.51
Revenue
$191,359,000.00
★ $726,437,000.00
Revenue This Year
$23.89
$19.55
Revenue Next Year
$15.89
$13.34
P/E Ratio
★ N/A
$34.47
Revenue Growth
38.09
★ 40.45
52 Week Low
$28.70
$15.86
52 Week High
$86.95
$30.96

Technical Indicators

Market Signals
Indicator
LASR
ACAD
Relative Strength Index (RSI) 37.92 34.82
Support Level $28.70 $15.86
Resistance Level $40.79 $22.71
Average True Range (ATR) 2.86 1.20
MACD -0.41 -0.11
Stochastic Oscillator 20.89 18.38

Price Performance

Historical Comparison
LASR
ACAD

About LASR nLIGHT Inc.

nLight Inc is a United States-based company provider of power semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It designs, manufactures, and sells a range of power semiconductor lasers and fiber lasers that are typically integrated into laser systems. It operates in two segments: Laser Products segment, which includes semiconductor lasers, fiber lasers, and directed energy products; and Advanced Development segment includes revenue earned from research and development contracts. The majority of its revenue is generated from the Laser segment. The company's geographical segments include North America, Asia Pacific, and EMEA, of which maximum revenue is derived from North America.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: